key: cord-0040209-73ddj4al authors: Thomas, Elizabeth title: Calls to the medical unit date: 2009-11-17 journal: Respiratory Physiotherapy DOI: 10.1016/b978-0-7020-3003-1.50016-4 sha: 28536c3bbffda431aafeb11e56115a5680e1d928 doc_id: 40209 cord_uid: 73ddj4al nan Medical patients regularly present with complicated multi-pathologies, often involving more than one system, each having a signifi cant impact on the others. This chapter looks at some of the more common pathologies that the on call physiotherapist will encounter, highlighting important points to consider when assessing and treating the medical patient. COPD exacerbations may be idiopathic or caused by bacterial or viral infection. Hypoxaemia will be the primary reason for the call out and the aim of physiotherapy is to establish the cause of hypoxaemia and treat as appropriate. Major causes of hypoxaemia in COPD exacerbation include: • Bronchospasm • Sputum retention • Consolidation. Others common causes include: • Cardiac event • Pneumothorax • Pulmonary embolus. Oxygen is a drug and should be prescribed. Prescription should include percentage, fl ow rate, delivery device and whether oxygen delivery is intermittent or continuous. Any changes to oxygen therapy should be discussed with medical staff. Prescription may be fl exible, for example 'maintain sats between 88% and 92%', in which case the FiO 2 can be changed as necessary until the desired saturation is reached. NB: Liaise with medical staff to establish target SpO 2 levels for each individual patient. They may be as low as 80-85% in chronically hypoxic patients. The role of the physiotherapist in relation to oxygen therapy includes: • Assessment of oxygenation prior to, during and following treatment • Ensuring the patient is receiving oxygen as prescribed • Informing medical staff of increasing oxygen requirements • Humidifi cation of FiO 2 >30% (or lower if secretions are tenacious). Some patients with COPD are classifi ed as oxygen sensitive and have a chronically raised PaCO 2 . They rely on a low PaO 2 to stimulate breathing, rather than an altered pH. This is called hypoxic drive. If too much oxygen is given, their stimulus to breathe (low PaO 2 ) is removed and the patient stops breathing, resulting in type II respiratory failure, sometimes called oxygen-induced respiratory acidosis. It is vital that all COPD patients receive controlled oxygen therapy until it is established whether they are oxygen sensitive (through arterial blood gas analysis). • Maintain adequate O 2 levels (saturations ≥90%) without precipitating respiratory acidosis or worsening hypercapnia. • Deliver O 2 via a controlled system such as a Venturi device. If a mask is not tolerated O 2 may be delivered via nasal cannulae. • Until it is established whether a COPD patient is O 2 sensitive, start FiO 2 at 0.28 and increase until PaO 2 is >7.6 kPa, without causing a signifi cant fall in pH. • The COPD patient with respiratory acidosis, despite optimal medical management and controlled oxygen therapy, will require NIV or IPPV. • If the COPD patient is not O 2 sensitive, increase FiO 2 until saturations are ≥90%. (Refer to Chapter 9.) • Only consider NIV following optimal medical management and controlled O 2 therapy. • COPD patients are at risk of pneumothorax with positive pressure ventilation. • Use controlled O 2 therapy when removing from NIV. Physiotherapy can play an important role in establishing the cause of frequent admissions in some patients and in helping to prevent such admissions (Table 12 .1). It is important to establish the ceiling of treatment agreed by the patient, their family and their medical team. IPPV may be deemed futile, and the fully informed Calls to the medical unit patient may decide that NIV is not in their best interest; treatment may consist solely of medications and physiotherapy. Assess the patient and formulate your plan and goals in line with what the patient wishes to achieve. There may be some disparity between what you perceive as optimal treatment and what the patient consents to. Some patients may wish to limit treatment to symptom control while others may feel that any intervention will worsen shortness of breath, outweighing any benefi ts gained, and thus decline what physiotherapy has to offer. These patients, who have had years of coping with unpleasant and disabling symptoms and have often had multiple inpatient admissions, are able to make truly informed choices. Patients with end-stage COPD, together with their families and carers, should have access to the full range of services offered by the multidisciplinary palliative care teams, including admission to hospices. Opioids, benzodiazepines, tricyclic antidepressants and oxygen therapy may be used for the palliation of breathlessness in patients unresponsive to other medical treatments. In the terminal stages of the disease, antisecretory agents may be useful. Optimal medical management is essential during acute exacerbation of asthma and may include magnesium infusion, inhaled or nebulized bronchodilators (beta-2 agonists and antimuscarinics), inhaled, nebulized, oral or intravenous corticosteroids, and theophyllines. Antibiotics will be used if there is evidence of infection (↑white cell count, neutrophils and CRP, ± pyrexia) (Table 12 .2). The tiring patient Inspiratory and expiratory polyphonic wheeze or a silent chest on auscultation are signs of deteriorating asthma Beware of 'normal' blood gases. Initially patients show type I respiratory failure ± hypocapnia. As they tire, pCO 2 rises, but ABGs may have been taken as pCO 2 is rising through the normal range. Look for signs of CO 2 retention/narcosis (see Chapter 9) • If you suspect the patient is deteriorating, ask for an urgent medical review • Use positioning to optimize respiratory muscle function and reduce work of breathing • Only use sputum clearance techniques if you think sputum retention is signifi cant in causing airway obstruction (refer to Chapter 6) • Avoid tiring patient further. Restrict to short, regular treatments • Non-invasive or invasive ventilation will be required for patients with type 2 respiratory failure (refer to Chapter 9) • ! NB: Check for pneumothorax before applying non-invasive ventilation (refer to CXR and auscultation sections) Calls to the medical unit PANCREATITIS Pancreatitis can be acute (one-off occurrence), chronic where it persists even after the cause has been removed, or hereditary. Causes include gallstones, excessive alcohol consumption, hypertriglyceridaemia, viral infection, trauma, vasculitis or pregnancy. The aim of physiotherapy is to identify and treat the cause of hypoxaemia (Table 12. 3). Renal failure is characterized by raised urea and creatinine levels. Electrolytes may also become deranged (Tables 12.4, 12.5 and 12.6). Oesophageal varices are extremely dilated submucosal veins in the oesophagus. They are a consequence of portal hypertension as seen in liver cirrhosis. They are very likely to bleed and are diagnosed via endoscopy (Table 12 .7). Interstitial lung disease (ILD) refers to a group of lung diseases characterized by infl ammation which often leads to pulmonary fi brosis. Fibrosis destroys the alveoli, interstitium and capillary network of the affected areas of lung resulting in a restrictive disorder (Table 12 .8). Pneumonia results from an infl ammation of the alveolar space, usually due to invasion by bacteria, viruses or fungi, or as a result of chemical or physical injury. In bacterial and fungal infection, alveoli fi ll with protein-rich fl uid and debris from white blood cells. Sputum production also increases (Table 12 .9). Interstitial pneumonia is characterized by patchy or diffuse infl ammation of the interstitium (the area between the alveoli). The alveoli do not contain signifi cant exudate. • CPAP is often required to maintain oxygenation • If type II respiratory failure develops, NIV or invasive ventilation will be required, if appropriate NB: Higher pressures will be required to ventilate 'stiff lungs' so ↑risk of pneumothorax • Monitor SpO 2 closely during treatment • Always ensure adequate O 2 delivery when moving the fi brotic patient. An ↑FiO 2 will probably be required • Dips in SpO 2 and breathlessness on exertion will resolve with rest and O 2 therapy. Be patient. It may take several minutes Adult cystic fi brosis (CF) patients will have their own independent airway clearance regime. It may comprise of PD ± self-percussion and ACBT, PEP mask, Flutter device or the Acapella. You do not need to be an expert in all these techniques, but during infective exacerbation you need to assess the effectiveness of the normal regime, and assist with sputum clearance if necessary. Patients may benefi t from PD and manual techniques performed by the physiotherapist. It is advisable to do one or two lung areas with each treatment. Treatment may need to be further modifi ed in the patient with dyspnoea, e.g. modifi ed PD, ↑emphasis on breathing control (Association of Chartered Physiotherapists in Cystic Fibrosis 2002) (Table 12 .10). include TB, pertussis, measles, aspiration of a foreign body or severe bacterial pneumonia Signs and symptoms include chronic purulent sputum production (sometimes several cupfuls a day), regular and often persistent respiratory tract infections, chronic cough, disturbed sleep, fatigue and fi nger clubbing. Bronchiectatic patients, like CF patients, usually have their own airway clearance regime. It may comprise of PD ± self-percussion and ACBT, PEP mask, Flutter device or the Acapella (see CF section above). In acute infective exacerbation they may require assistance to achieve effective sputum clearance. Common issues include type I respiratory failure, haemoptysis and infection control References Association of Chartered Physiotherapists in Cystic Fibrosis (2002) Clinical guidelines for the physiotherapy management of cystic fi brosis Chronic obstructive pulmonary disease: management of chronic obstructive pulmonary disease in adults in primary and secondary care Respiratory physiology: the essentials Pulmonary pathophysiology: the essentials